Notes
The study was supported by Eli Lilly and Company.
Reference
Clouth J, et al. Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data. Health Economics Review : 27 Aug 2018. Available from: URL: https://doi.org/10.1186/s13561-018-0199-1
Rights and permissions
About this article
Cite this article
Liver cancer costs post-sorafenib treatment in Germany. PharmacoEcon Outcomes News 811, 17 (2018). https://doi.org/10.1007/s40274-018-5246-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5246-y